Skip to main content
main-content
Top

25-07-2017 | Mesothelioma | Article

Novel insights into mesothelioma biology and implications for therapy

Authors:
Timothy A Yap, Joachim G Aerts, Sanjay Popat, Dean A Fennell

Abstract

Malignant mesothelioma is a universally lethal cancer that is increasing in incidence worldwide. There is a dearth of effective therapies, with only one treatment (pemetrexed and cisplatin combination chemotherapy) approved in the past 13 years. However, the past 5 years have witnessed an exponential growth in our understanding of mesothelioma pathobiology, which is set to revolutionize therapeutic strategies. From a genomic standpoint, mesothelioma is characterized by a preponderance of tumour suppressor alterations, for which novel therapies are currently in development. Other promising antitumour agents include inhibitors against angiogenesis, mesothelin and immune checkpoints, which are at various phases of clinical trial testing.

Nat Rev Cancer 2017; 17, 475–488. doi:10.1038/nrc.2017.42

 

Please log in to get access to this content

Related topics